The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy

Journal of the American College of Cardiology

Volumn 47, Issue 9, 2006, Pages 1871-1881

  Nikolaidis, Lazaros A ^a   Poornima, Indu ^a   Parikh, Pratik ^a   Magovern, Megan ^a   Shen, You Tang ^a   Shannon, Richard P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; GLUCAGON; METOPROLOL SUCCINATE; MICROSPHERE; NORADRENALIN;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONSCIOUSNESS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; GLUCOSE TRANSPORT; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMICS; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; MALE; MUSCLE BLOOD FLOW; NONHUMAN; PERFUSION; PRIORITY JOURNAL; VASCULAR RESISTANCE;

ADRENERGIC ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ANIMALS; CARBAZOLES; CARDIOMYOPATHY, DILATED; DOGS; HEART RATE; HEMODYNAMIC PROCESSES; ISOPROTERENOL; METOPROLOL; MYOCARDIUM; PROPANOLAMINES; REGIONAL BLOOD FLOW; VENTRICULAR FUNCTION, LEFT;

EID: 33646176138     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.082     Document Type: Article

References (33)

1. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). a randomized trial. Lancet 353 (1999) 9-13
4. Australia-New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349 (1997) 375-380
5. Packer M., Coats A.J.S., Fowler M.B., et al., Carvedilol prospective randomized cumulative survival study group (COPERNICUS). Effect of carvedilol on survival in severe heart failure. N Engl J Med 344 (2001) 1651-1658
6. Poole-Wilson P.A., Swedberg J.G., Cleland J.G.F., et al. Comparison of carvedilol or metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). randomized controlled trial. Lancet 362 (2003) 7-13
7. 1-receptor? A perspective on the results of the COMET trial. J Card Fail 9 (2003) 429-443
8. Bristow M.R., Feldman A.M., Adams Jr. K.F., and Goldstein S. Selective versus nonselective β-blockade for heart failure therapy. are there lessons to be learned from the COMET trial?. J Card Fail 9 (2003) 444-453
9. Shepherd A.M.M. A clinical pharmacologist's response to Dr. Milton Packer's perspective on the results of the COMET trial. J Card Fail 9 (2003) 454-457
10. Nikolaidis L.A., Doverspike A., Huerbin R., Hentosz T., and Shannon R.P. Angiotensin converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin mediated, NO-dependent mechanism. Circulation 105 (2002) 2785-2790
11. Shen W., Asai K., Uechi M., Mathier M.A., Shannon R.P., Vatner S.F., and Ingwall J.S. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs. Circulation 100 (1999) 2113-2118
12. Nikolaidis L.A., Sturzu A., Stolarski C., Elahi D., Shen Y.T., and Shannon R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61 (2004) 297-306
13. Eichhorn E.J., Heesch C.M., Barnett J.H., et al. Effects of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy. a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24 (1994) 1310-1320
14. Kiuchi K., Sato N., Shannon R.P., Vatner D.E., Morgan K., and Vatner S.F. Depressed β-adrenergic receptor- and endothelium-mediated vasodilation in conscious dogs with heart failure. Circ Res 73 (1993) 1013-1023
15. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetiologia 43 (2000) 533-549
16. Kiuchi K., Shannon R.P., Komamura K., et al. Myocardial β-adrenergic receptor function during the development of pacing induced heart failure. J Clin Invest 91 (1993) 907-914
17. Metra M., Giubbini R., Nodari S., et al. Differential effects of β-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
18. Kukin M.L., Kalman J., Mannino M., Freudenberger R., Buchholz C., and Ocampo O. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 77 (1996) 486-491
19. Kukin M.L., Kalman J., Charney R.H., et al. Prospective randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 (1999) 2645-2651
20. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
21. Maack C., Elter T., Nickenig G., et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol 38 (2001) 939-946
22. DiLenarda A., Sabbadini G., Salvatore L., et al. Long term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 33 (1999) 1926-1934
23. Uber P.A., Nasca P.F., Scott R.L., et al. Carvedilol but not metoprolol XL is associated with dose dependent decline in B-type natriuretic peptide levels. J Card Fail 8 (2002) S59
24. Hryniewicz K., Androne A.S., Hudaihed A., and Katz S.D. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 108 (2003) 971-976
25. Nagano T., O'Harrow S., Sponer G., and Zimmer H.G. Norepinephrine induced changes in rat heart function, metabolism, and weight are antagonized by carvedilol. J Cardiovasc Pharmacol 21 (1993) 530-536
26. Razolini R., Tarantini G., Boffa G.M., Orlando S., and Iliceto S. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. Ital Heart J 5 (2004) 517-522
27. Cohn J., Archibald D.G., Ziesche S., et al. Effects of vasodilator therapy on mortality in chronic heart failure. Results of Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
28. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. the antihypertensive and lipid lowering treatment to prevent heart attack trial. JAMA 283 (2000) 1967-1975
29. Azevedo E.R., Kubo T., Mak S., et al. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure. differential effects on sympathetic activity. Circulation 104 (2001) 2194-2199
30. Heitmann M., Davidsen U., Stokholm K.H., et al. Renal and cardiac function during alpha 1-beta blockade in congestive heart failure. Scand J Clin Lab Invest 62 (2002) 97-104
31. Wallhaus T.R., Taylor M., DeGrado T.R., Russell D.C., Stanko P., Nickles R.J., and Stone C.K. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103 (2001) 2441-2446
32. Podbregar M., and Voga G. Effect of selective and non selective beta blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail 8 (2003) 369-378
33. Kiuchi K., Shannon R.P., Komamura K., et al. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 91 (1993) 907-914